Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...

Organon has shared positive results from a long-term extension (LTE) study of its Vtama (tapinarof) cream, 1% in atopic ...

Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...

The Prime Minister, Justin Trudeau, today issued the following statement on International Women's Day: "Women in Canada have made transformative progress in shaping our country for the better. Today, ...

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...

Today, on International Women's Day, the Society of Obstetricians and Gynaecologists of Canada (SOGC) is calling on women to ...

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...

A protein called NF-kB c-Rel has been found to intensify the symptoms of psoriasis, offering a potential new target for treatments. Researchers at Case Western Reserve University School of Medicine ...

Currently available fixed combination topicals have robust efficacy, and the recently approved cream formulations of tapinarof and roflumilast appear to have efficacy that may be higher than ...

Dermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches the market, and it has just cut a deal to defray those costs. The Roivant group ...

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of the drug.